446 related articles for article (PubMed ID: 17234768)
21. Different cascades in the signaling pathway of two vascular endothelial growth factor (VEGF) receptors for the VEGF-mediated murine hepatocellular carcinoma development.
Yoshiji H; Noguchi R; Kuriyama S; Yoshii J; Ikenaka Y; Yanase K; Namisaki T; Kitade M; Yamazaki M; Uemura M; Fukui H
Oncol Rep; 2005 May; 13(5):853-7. PubMed ID: 15809749
[TBL] [Abstract][Full Text] [Related]
22. Inhibition of multiple vascular endothelial growth factor receptors (VEGFR) blocks lymph node metastases but inhibition of VEGFR-2 is sufficient to sensitize tumor cells to platinum-based chemotherapeutics.
Sini P; Samarzija I; Baffert F; Littlewood-Evans A; Schnell C; Theuer A; Christian S; Boos A; Hess-Stumpp H; Foekens JA; Setyono-Han B; Wood J; Hynes NE
Cancer Res; 2008 Mar; 68(5):1581-92. PubMed ID: 18316624
[TBL] [Abstract][Full Text] [Related]
23. Vascular endothelial growth factor and vascular targeting of solid tumors.
Brekken RA; Thorpe PE
Anticancer Res; 2001; 21(6B):4221-9. PubMed ID: 11908675
[TBL] [Abstract][Full Text] [Related]
24. Localization of vascular endothelial growth factor-D in malignant melanoma suggests a role in tumour angiogenesis.
Achen MG; Williams RA; Minekus MP; Thornton GE; Stenvers K; Rogers PA; Lederman F; Roufail S; Stacker SA
J Pathol; 2001 Feb; 193(2):147-54. PubMed ID: 11180159
[TBL] [Abstract][Full Text] [Related]
25. Enhanced susceptibility of irradiated tumor vessels to vascular endothelial growth factor receptor tyrosine kinase inhibition.
Zips D; Eicheler W; Geyer P; Hessel F; Dörfler A; Thames HD; Haberey M; Baumann M
Cancer Res; 2005 Jun; 65(12):5374-9. PubMed ID: 15958586
[TBL] [Abstract][Full Text] [Related]
26. Anti-VEGF antibody in experimental hepatoblastoma: suppression of tumor growth and altered angiogenesis.
McCrudden KW; Hopkins B; Frischer J; Novikov A; Huang J; Kadenhe A; New T; Yokoi A; Yamashiro DJ; Kandel JJ; Middlesworth W
J Pediatr Surg; 2003 Mar; 38(3):308-14; discussion 308-14. PubMed ID: 12632340
[TBL] [Abstract][Full Text] [Related]
27. VEGF-D in association with VEGFR-3 promotes nodal metastasis in human invasive lobular breast cancer.
van Iterson V; Leidenius M; von Smitten K; Bono P; Heikkilä P
Am J Clin Pathol; 2007 Nov; 128(5):759-66. PubMed ID: 17951197
[TBL] [Abstract][Full Text] [Related]
28. Tumor-induced activation of lymphatic endothelial cells via vascular endothelial growth factor receptor-2 is critical for prostate cancer lymphatic metastasis.
Zeng Y; Opeskin K; Goad J; Williams ED
Cancer Res; 2006 Oct; 66(19):9566-75. PubMed ID: 17018613
[TBL] [Abstract][Full Text] [Related]
29. Selective blockade of vascular endothelial growth factor receptor 2 with an antibody against tumor-derived vascular endothelial growth factor controls the growth of human pancreatic adenocarcinoma xenografts.
Holloway SE; Beck AW; Shivakumar L; Shih J; Fleming JB; Brekken RA
Ann Surg Oncol; 2006 Aug; 13(8):1145-55. PubMed ID: 16791450
[TBL] [Abstract][Full Text] [Related]
30. Impaired angiogenesis after hindlimb ischemia in type 2 diabetes mellitus: differential regulation of vascular endothelial growth factor receptor 1 and soluble vascular endothelial growth factor receptor 1.
Hazarika S; Dokun AO; Li Y; Popel AS; Kontos CD; Annex BH
Circ Res; 2007 Oct; 101(9):948-56. PubMed ID: 17823371
[TBL] [Abstract][Full Text] [Related]
31. Ganglioside GM3 inhibits VEGF/VEGFR-2-mediated angiogenesis: direct interaction of GM3 with VEGFR-2.
Chung TW; Kim SJ; Choi HJ; Kim KJ; Kim MJ; Kim SH; Lee HJ; Ko JH; Lee YC; Suzuki A; Kim CH
Glycobiology; 2009 Mar; 19(3):229-39. PubMed ID: 18974200
[TBL] [Abstract][Full Text] [Related]
32. Angiogenesis inhibition by vascular endothelial growth factor receptor-2 blockade reduces stromal matrix metalloproteinase expression, normalizes stromal tissue, and reverts epithelial tumor phenotype in surface heterotransplants.
Vosseler S; Mirancea N; Bohlen P; Mueller MM; Fusenig NE
Cancer Res; 2005 Feb; 65(4):1294-305. PubMed ID: 15735015
[TBL] [Abstract][Full Text] [Related]
33. Expression of vascular endothelial growth factor receptor-3 (VEGFR-3) in human prostate.
Li R; Younes M; Wheeler TM; Scardino P; Ohori M; Frolov A; Ayala G
Prostate; 2004 Feb; 58(2):193-9. PubMed ID: 14716745
[TBL] [Abstract][Full Text] [Related]
34. mTOR inhibitor RAD001 (everolimus) has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor.
Lane HA; Wood JM; McSheehy PM; Allegrini PR; Boulay A; Brueggen J; Littlewood-Evans A; Maira SM; Martiny-Baron G; Schnell CR; Sini P; O'Reilly T
Clin Cancer Res; 2009 Mar; 15(5):1612-22. PubMed ID: 19223496
[TBL] [Abstract][Full Text] [Related]
35. VEGF-D promotes the metastatic spread of tumor cells via the lymphatics.
Stacker SA; Caesar C; Baldwin ME; Thornton GE; Williams RA; Prevo R; Jackson DG; Nishikawa S; Kubo H; Achen MG
Nat Med; 2001 Feb; 7(2):186-91. PubMed ID: 11175849
[TBL] [Abstract][Full Text] [Related]
36. Involvement of the vascular endothelial growth factor receptor-1 in murine hepatocellular carcinoma development.
Yoshiji H; Kuriyama S; Yoshii J; Ikenaka Y; Noguchi R; Yanase K; Namisaki T; Kitade M; Yamazaki M; Tsujinoue H; Masaki T; Fukui H
J Hepatol; 2004 Jul; 41(1):97-103. PubMed ID: 15246214
[TBL] [Abstract][Full Text] [Related]
37. Immunohistochemical analysis of VEGF-C/VEGFR-3 system and lymphatic vessel extent in normal and adenomatous human pituitary tissues.
Onofri C; Losa M; Uhl E; Stalla GK; Renner U
Exp Clin Endocrinol Diabetes; 2008 Mar; 116(3):152-7. PubMed ID: 18205092
[TBL] [Abstract][Full Text] [Related]
38. Clinicopathological and prognostic significance of vascular endothelial growth factors (VEGF)-C and -D and VEGF receptor 3 in invasive breast carcinoma.
Mylona E; Alexandrou P; Mpakali A; Giannopoulou I; Liapis G; Markaki S; Keramopoulos A; Nakopoulou L
Eur J Surg Oncol; 2007 Apr; 33(3):294-300. PubMed ID: 17129704
[TBL] [Abstract][Full Text] [Related]
39. Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3.
Hu-Lowe DD; Zou HY; Grazzini ML; Hallin ME; Wickman GR; Amundson K; Chen JH; Rewolinski DA; Yamazaki S; Wu EY; McTigue MA; Murray BW; Kania RS; O'Connor P; Shalinsky DR; Bender SL
Clin Cancer Res; 2008 Nov; 14(22):7272-83. PubMed ID: 19010843
[TBL] [Abstract][Full Text] [Related]
40. Angiogenesis and radiation response modulation after vascular endothelial growth factor receptor-2 (VEGFR2) blockade.
Li J; Huang S; Armstrong EA; Fowler JF; Harari PM
Int J Radiat Oncol Biol Phys; 2005 Aug; 62(5):1477-85. PubMed ID: 16029810
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]